Dr. Reddy’s Announces the Launch of Desloratadine ODT (Orally Disintegrating Tablets)

  Dr. Reddy’s Announces the Launch of Desloratadine ODT (Orally Disintegrating
  Tablets)

Business Wire

HYDERABAD, India -- January 25, 2013

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched
Desloratadine ODT (2.5 mg & 5 mg), a bioequivalent generic version of
Clarinex® Reditabs® (desloratadine) in the US market on January 24, 2013. Dr.
Reddy’s ANDA for Desloratadine ODT is approved by the United States Food &
Drug Administration (USFDA).

The Clarinex® Reditabs® brand had U.S. sales of approximately $5.3 Million for
the most recent twelve months ending November 2012 according to IMS Health*.

Dr. Reddy’s Desloratadine ODT 2.5 mg & 5 mg are available in unit dose
packages of 30 (5x6).

Disclaimer

This press release includes forward-looking statements, as defined in the U.S.
Private Securities Litigation Reform Act of 1995. We have based these
forward-looking statements on our current expectations and projections about
future events. Such statements involve known and unknown risks, uncertainties
and other factors that may cause actual results to differ materially. Such
factors include, but are not limited to, changes in local and global economic
conditions, our ability to successfully implement our strategy, the market
acceptance of and demand for our products, our growth and expansion,
technological change and our exposure to market risks. By their nature, these
expectations and projections are only estimates and could be materially
different from actual results in the future.

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global
pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses - Pharmaceutical
Services and Active Ingredients, Global Generics and Proprietary Products –
Dr. Reddy’s offers a portfolio of products and services including APIs, custom
pharmaceutical services, generics, biosimilars, differentiated formulations
and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular,
diabetology, oncology, pain management, anti-infective and pediatrics. Major
markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa,
Romania, and New Zealand. For more information, log on to: www.drreddys.com

Clarinex^® Reditabs^® are registered trademarks of Schering Corp., a
subsidiary of Merck & Co., Inc.

*IMS National Sales Perspectives: Retail and Non-Retail MAT November 2012

Contact:

Dr. Reddy’s Laboratories Ltd.
Investors and Financial Analysts:
Kedar Upadhye, +91-40-66834297
kedaru@drreddys.com
or
Saunak Savla, +91-40-49002135
saunaks@drreddys.com
or
Milan Kalawadia (USA), +1 908-203-4931
mkalawadia@drreddys.com
or
Media:
S Rajan, +91-40-49002445
rajans@drreddys.com
 
Press spacebar to pause and continue. Press esc to stop.